Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

Delayed Quote. Delayed Nasdaq - 05/21 10:00:00 pm
86.91 USD   +0.30%
05/17DEXCOM : Announces Upcoming Conference Presentation
BU
05/03DEXCOM : revenue jumps ahead of launch of latest wearable glucose mo..
AQ
05/02DEXCOM : 1Q Earnings Snapshot
AQ
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/15/2018 05/16/2018 05/17/2018 05/18/2018 05/21/2018 Date
87.26(c) 86.54(c) 86.91(c) 86.65(c) 86.91(c) Last
719 094 673 128 696 380 432 622 336 307 Volume
-0.77% -0.83% +0.43% -0.30% +0.30% Change
More quotes
Financials (USD)
Sales 2018 860 M
EBIT 2018 -40,8 M
Net income 2018 -45,6 M
Finance 2018 185 M
Yield 2018 -
Sales 2019 992 M
EBIT 2019 -6,47 M
Net income 2019 -19,5 M
Finance 2019 272 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 8,69x
EV / Sales2019 7,44x
Capitalization 7 655 M
More Financials
Company
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes.Its products include Dexcom G4 PLATINUM System, Dexcom studio and Mobile apps.The company was... 
More about the company
Surperformance© ratings of DexCom, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on DEXCOM, INC.
05/17DEXCOM : Announces Upcoming Conference Presentation
BU
05/03DEXCOM : revenue jumps ahead of launch of latest wearable glucose monitor for di..
AQ
05/03DEXCOM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
05/02DEXCOM : 1Q Earnings Snapshot
AQ
05/02DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..
AQ
05/02DEXCOM : Reports First Quarter 2018 Financial Results
BU
04/10DEXCOM, INC. : Free Research Report as DexCom’s Quarterly Revenues Surged 29%; T..
AC
04/04DEXCOM SCHEDULES FIRST QUARTER 2018 : 30 p.m. Eastern Time.
BU
03/30NEW REPORT FOCUSING ON REAL-TIME E-H : Real-Time E-Healthcare System Market Stud..
AQ
03/30DEXCOM : wins FDA approval for next generation of glucose monitors for diabetes
AQ
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
05/16Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 billion
RE
05/16Sivantos and Widex in $8 billion merger to create No.3 in hearing aids
RE
05/10Shares of Medical Technology Companies Down After Hours on New Study--Market ..
DJ
05/10HEART DEVICE PROCEDURE IS NO BETTER : Study
DJ
05/08WILLIAM DEMANT A/S : shares plummet after growth outlook fails to impress
RE
More sector news : Medical Equipment, Supplies & Distribution - NEC
Latest Tweets
05/21Dexcom's newest diabetes device can read your blood sugar without any blood, ..
14
05/20Dexcom's newest diabetes device can read your blood sugar without any blood, ..
21
05/19Dexcom's newest diabetes device can read your blood sugar without any blood, ..
11
05/19Dexcom $DXCM Insider Sells $859,000.00 in Stock  
05/18Dexcom's newest diabetes device can read your blood sugar without any blood, ..
13
More tweets
Qtime:90
News from SeekingAlpha
05/11Premarket analyst action - healthcare 
05/02DexCom (DXCM) Q1 2018 Results - Earnings Call Transcript 
05/02DexCom Q1 revenues up 30%; guidance raised; shares up 3% after hours 
05/02DexCom beats by $0.01, beats on revenue 
05/01Notable earnings after Wednesday?s close 
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | DXCM | US2521311074 | 4-Traders
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 83,6 $
Spread / Average Target -3,5%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer President, Chief Executive Officer & Director
Terrance H. Gregg Executive Chairman
Jeffrey C. Moy Senior Vice President-Operations
Quentin Blackford Chief Financial Officer
Jacob Leach Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.50.98%7 655
MEDTRONIC PLC5.40%115 356
BAXTER INTERNATIONAL9.22%37 832
ALIGN TECHNOLOGY, INC.11.20%23 461
ZIMMER BIOMET HOLDINGS-4.66%23 386
TERUMO CORP20.63%22 270